LBA35: Positive Efficacy for Eftilagimod plus Pembrolizumab in Patients with Head and Neck Squamous Cell Carcinoma

Claus Andrup Kristensen, Copenhagen University hospital Rigshospitalet, Denmark, gives his perspective of LBA35 he presented at ESMO 2024. The TACTI-003 study is a randomized phase IIB trial with patients having CPS ≥1, comparing pembrolizumab plus eftilagimod vs pembrolizumab alone in patients with recurrent or metastatic head and neck squamous cell carcinoma.